Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2009 3
2012 3
2013 2
2014 4
2015 10
2016 16
2017 13
2018 5
2019 3
2020 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
TGF-beta: a master immune regulator.
Larson C, Oronsky B, Carter CA, Oronsky A, Knox SJ, Sher D, Reid TR. Larson C, et al. Among authors: carter ca. Expert Opin Ther Targets. 2020 May;24(5):427-438. doi: 10.1080/14728222.2020.1744568. Epub 2020 Apr 12. Expert Opin Ther Targets. 2020. PMID: 32228232 Review.
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Oronsky B, Ma PC, Morgensztern D, Carter CA. Oronsky B, et al. Among authors: carter ca. Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Neoplasia. 2017. PMID: 29091800 Free PMC article. Review.
What's New in SCLC? A Review.
Oronsky B, Reid TR, Oronsky A, Carter CA. Oronsky B, et al. Among authors: carter ca. Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Neoplasia. 2017. PMID: 28888101 Free PMC article. Review.
The war on cancer: a military perspective.
Oronsky B, Carter CA, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T. Oronsky B, et al. Among authors: carter ca. Front Oncol. 2015 Jan 26;4:387. doi: 10.3389/fonc.2014.00387. eCollection 2014. Front Oncol. 2015. PMID: 25674537 Free PMC article. Review.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. Oronsky B, et al. Among authors: carter ca. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Expert Opin Investig Drugs. 2017. PMID: 27935336 Review.
RRx-001 protects against cisplatin-induced toxicities.
Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P. Oronsky B, et al. Among authors: carter ca. J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17. J Cancer Res Clin Oncol. 2017. PMID: 28417195
61 results